Prostatype Genomics AB (publ) (PROGEN.ST)
- Previous Close
1.7800 - Open
1.7600 - Bid 1.7550 x --
- Ask 1.7950 x --
- Day's Range
1.7600 - 1.7600 - 52 Week Range
1.5200 - 56.3636 - Volume
2,000 - Avg. Volume
32,971 - Market Cap (intraday)
12.03M - Beta (5Y Monthly) 0.34
- PE Ratio (TTM)
-- - EPS (TTM)
-2,874.5500 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Prostatype Genomics AB manufactures, markets, and sells the prognostic gene tests. It offers Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, Gleason Score, and Tumor Stage, as well as calculates the P-score. The company's test is based on database containing prostate cancer patients, as well as provides decision support for patients and doctors when making a treatment decision. Prostatype Genomics AB (publ) was incorporated in 2007 and is based in Solna, Sweden.
www.prostatypegenomics.com6
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: PROGEN.ST
View MorePerformance Overview: PROGEN.ST
Trailing total returns as of 5/6/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PROGEN.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PROGEN.ST
View MoreValuation Measures
Market Cap
12.17M
Enterprise Value
21.15M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
26.87
Price/Book (mrq)
0.36
Enterprise Value/Revenue
106.29
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-56.00%
Return on Equity (ttm)
-141.21%
Revenue (ttm)
1.92M
Net Income Avi to Common (ttm)
-41.05M
Diluted EPS (ttm)
-2,874.5500
Balance Sheet and Cash Flow
Total Cash (mrq)
9.42M
Total Debt/Equity (mrq)
0.20%
Levered Free Cash Flow (ttm)
-16.09M